Safety of parathyroid hormone for the treatment of osteoporosis

被引：52

作者：

Miller P.D. ^{[1
]}

机构：

[1] Colorado Center for Bone Research, Lakewood, CO 80227

来源：

Current Osteoporosis Reports | 2008年 / 6卷 / 1期

关键词：

Osteoporosis; Gout; Parathyroid Hormone; Hypercalcemia; Serum Uric Acid;

D O I：

10.1007/s11914-008-0003-y

中图分类号：

学科分类号：

摘要：

Teriparatide (recombinant human 1-34 parathyroid hormone) has been registered for the treatment of postmenopausal osteoporosis and osteoporosis in men for more than 5 years, whereas 1-84 parathyroid hormone has just recently been registered in Europe for osteoporosis management. Therefore, more data are available regarding the long-term safety of teriparatide. The issues to be considered are the effects of the registered dose of teriparatide (20 μg/day) on the incidence of hypercalcemia, hypercalciuria, and hyperuricemia, and the US Food and Drug Administration's "black-box" warning regarding osteogenic sarcoma in the rat model. This review discusses these issues and provides the author's extensive clinical experience and advice on the use of teriparatide in clinical practice. © Springer Science+Business Media, LLC 2008.

引用

页码：12 / 16

页数：4

共 41 条

[1]

Neer R.M., Arnaud C.D., Zanchetta J.R., Et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, pp. 1434-1441, (2001)

[2]

Orwoll E.S., Scheele W.H., Paul S., Et al., The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis, J Bone Miner Res, 18, pp. 9-17, (2003)

[3]

Saag K.G., Shane E., Boonen S., Et al., Teriparatide or alendronate in glucocorticoid-induced osteoporosis, N Engl J Med, 357, pp. 2028-2039, (2007)

[4]

Greenspan S.L., Bone H.G., Macciott T.B., Et al., Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1-84): Results from the TOP study, J Bone Miner Res, 20, SUPPL. 1, (2005)

[5]

Miller P.D., Bilezikian J.P., Deal C., Harris S.T., Clinical use of teriparatide in the real world: Initial insights, Endocr Pract, 10, pp. 139-148, (2004)

[6]

Hodsman A.B., Bauer D.C., Dempster D.W., Et al., Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use, Endocr Rev, 26, pp. 688-703, (2005)

[7]

Tashjian A.H., Gagel R.F., Teriparatide (human parathyroid hormone 1-34): Two and a half years of experience on the use and safety of the drug for the treatment of osteoporosis, J Bone Miner Res, 21, pp. 354-365, (2006)

[8]

Miller P.D., Silverman S., Gold D.T., Et al., Rationale, objectives, and design of the Direct Analysis of Nonvertebral fracture in the Community Experience (DANCE) study, Osteoporos Int, 17, pp. 85-90, (2006)

[9]

Wagman R., Miller P.D., The use of teriparatide and PTH (1-84) for the treatment of osteoporosis, Clin Rev Bone Mineral Metab, 4, pp. 1-13, (2006)

[10]

Miller P.D., Shergy W.J., Body J.J., Et al., Long-term reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate, J Rheumatol, 32, pp. 1556-1562, (2005)

← 1 2 3 4 5 →